down-regulates survivin to facilitate paclitaxel sensitization in human breast carcinoma cell lines.
is a tripyrrole first characterized from Serratia marcescens, which forms beautiful pillar box red colonies and S.
They produce prodigiosin
at 25[degrees]C-28[degrees]C (77[degrees]F-82.
PIGMENT OF THE BACTERIUM SERRATIA MARCESCENS MAY FUNCTION TO SPILL EXCESS CELLULAR ENERGY.
is a red pigment isolated from a few species of bacteria such as, Serratia, Pseudomonas and Streptomyces (11) and is a typical alkaloid compound produced as a secondary metabolite.
is currently being evaluated for pre-clinical trials as a potential therapy for pancreatic cancer.
synthesis on Tryptic Soy and Nutrient Agar supplemented with glucose, lactose, sucrose, or sorbitol was evaluated and colonies were subjected to growth on Triple Sugar Iron slants.
Serratia marcescens CR2B produces the red pigment prodigiosin
characteristic of the species and probably adheres at least for that reason.
Antimetastatic effect of prodigiosin
through inhibition of tumor invasion.
Aida has seven additional pipeline drugs in advanced stages of development: three gene therapy cancer drugs including patented Rh-Apo2l nearing the end of phase I trials, Prodigiosin
for treating pancreatic cancer, Anti-CD86 monoclonal anti-body for the treatment of immunity-related diseases, Anti-CTLA-4 monoclonal anti-body for the treatment of tumors and stroke recovery medicine SYO2.
Serratia marcescens strain Nima expresses the red, intracellular pigment prodigiosin
Aida Pharmaceuticals is developing a method to utilize the biochemical properties of Prodigiosin
to create a non-invasive treatment for pancreatic cancer.